Skip to main content
main-content
Top

03-01-2016 | Diabetes prevention | Book chapter | Article

Prevention of Type 2 Diabetes Mellitus

Author: Edward S. Horton

Publisher: Springer International Publishing

share
SHARE

Abstract

This chapter reviews the results of important studies on the prevention of type 2 diabetes (DM2) and its long term complications in people with impaired glucose tolerance (IGT). Randomized controlled trials of lifestyle interventions focusing on diet, weight reduction and increased physical exercise have resulted in relative risk reductions (RR’s) for progression to diabetes ranging from 28.5 to 58 % during the active phases of the study and continued RR’s for the development of DM2 during long-term follow-up. Lifestyle interventions have also resulted in sustained improvents in multiple cardiovascular risk factors including improvements in blood pressure, serum lipids and the metabolic syndrome. In one of the longest studies to date, the DA Qing study, there was aslo a significant reduction in cardiovascular mortality after 23 years of follow-up.
Several medication trials are also reviewed. The risk reductions ranged from 25 to 79 % depending on the agent used. However, no long-term benefits from any of the study medications have been observed after discontinuation of theraphy. Finally, the results of weight loss therapies, including bariatric surgery, are discussed and general recommendations for patient screening and management are provided.
Literature
1.
International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015.
2.
Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14. CrossRefPubMedPubMedCentral
3.
Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults. JAMA. 2002;287:356–9. CrossRefPubMed
4.
Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its Burden in the United States, 2014. Atlanta: U.S. Department of Health and Human Services; 2014.
5.
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19. CrossRefPubMed
6.
U.K. Prospective Diabetes Study Group. Perspectives in diabetes. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58. CrossRef
7.
Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29:1263–8. [PMID: 16732006] [Abstract/Free Full Text]. CrossRefPubMed
8.
Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961–9. CrossRefPubMed
9.
Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481–6. CrossRefPubMed
10.
Knowler WC, Narayan KM, Hanson RL, et al. Preventing non-insulin-dependent diabetes. Diabetes. 1995;44:483–8. CrossRefPubMed
11.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35 Suppl 1:S64–71. CrossRefPubMedCentral
12.
Mann DM, Carson AP, Shimbo D, et al. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care. 2010;33(10):2190–5. CrossRefPubMedPubMedCentral
13.
Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnosis of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-Hr glucose values and effects of gender, race and age. Metab Syndr Metab Disord. 2014;12(5):258–68. CrossRef
14.
American Association of Clinical Endocrinologists and American College of Endocrinology. Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015-executive summary. Endocr Pract. 2015;21(4):413–37. CrossRef
15.
Wilson WF, Dagostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72. CrossRefPubMed
16.
Lorenzo C, Williams K, Hunt KJ, et al. National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes federation and WHO definitions of the metabolic syndrome as predictors of cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13. CrossRefPubMed
17.
Joslin E. The prevention of diabetes mellitus. JAMA. 1921;76:79–84. CrossRef
18.
Malik VS, Willett WC, Hu FB. Sugar-sweetened beverages and BMI in children and adolescents: reanalyses of a meta-analysis. Am J Clin Nutr. 2009;89(1):438–9. CrossRefPubMed
19.
Bazzano LA, Li TY, Joshipura KJ, Hu FB. Intake of fruit, vegetables, and fruit juices and risk of diabetes in women. Diabetes Care. 2008;31(7):1311–7. CrossRefPubMedPubMedCentral
20.
Jeon CY, Lokken RP, Hu FB, et al. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. 2007;30(3):744–52. CrossRefPubMed
21.
Qi L, Hu FB, Hu G. Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med. 2008;8(6):519–32. CrossRefPubMed
22.
Field AE, Willett WC, Lissner L, Colditz GA. Dietary fat and weight gain among women in the Nurses’ Health Study. Obesity. 2007;15(4):967–76. CrossRefPubMed
23.
Hu FB, Sigal RJ, Rich-Edwards JW, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women. JAMA. 1999;282:1433–9. CrossRefPubMed
24.
Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance (“borderline diabetes”). Diabetologia. 1979;16:25–30. CrossRefPubMed
25.
Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia. 1982;22:73–8. CrossRefPubMed
26.
Sartor G, Scherstén B, Carlström S, Melander A, Nordén A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29:41–9. CrossRefPubMed
27.
Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44. CrossRefPubMed
28.
Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474–80.
29.
Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50. CrossRefPubMed
30.
Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–9. CrossRefPubMed
31.
Lindstrom J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-ter4m follow-up of the randomized Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56(2):284–93. CrossRefPubMed
32.
The DPP Research Group. Baseline characteristics of the randomized cohort. Diabetes Care. 2000;23:1619–29. CrossRef
33.
The DPP Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. CrossRef
34.
The DPP Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150–6. CrossRef
35.
The DPP Research Group. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7. CrossRef
36.
The DPP Research Group. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61:1075–81. CrossRef
37.
The DPP Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program. Diabetes. 2005;54:2404–14. CrossRef
38.
Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–9. CrossRefPubMedPubMedCentral
39.
The DPP Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28:888–94. CrossRef
40.
The DPP Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566–72. CrossRef
41.
Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86. CrossRefPubMedCentral
42.
The Diabetes Prevention Program Outcomes Study Research Group. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30(1):46–55. CrossRef
43.
Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152–62. CrossRefPubMed
44.
Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97. CrossRefPubMed
45.
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacologic treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–803. CrossRefPubMed
46.
The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096–105. CrossRef
47.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43. CrossRefPubMed
48.
DeFronzo RA, Banerji MA, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) Study. BMC Endocr Disord. 2009;9:17. CrossRefPubMedPubMedCentral
49.
Yang W, Lin L, Qi J, et al. The preventive effect of Acarbose and Metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab. 2001;17:131–6.
50.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7. CrossRefPubMed
51.
Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006;12 Suppl 1:25–30. CrossRefPubMed
52.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61. CrossRefPubMed
53.
Pories WJ, MacDonald Jr KG, Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-year follow-up. Am J Clin Nutr. 1992;55:582S–5. PubMed
54.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Rous-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–85. PubMedPubMedCentral
55.
Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–23. CrossRefPubMed
56.
Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237:751–8. PubMedPubMedCentral
57.
Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93. CrossRefPubMed
58.
Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695–703. CrossRefPubMed
59.
American College of Endocrinology Task Force on the Prevention of Diabetes. Diagnosis and management of prediabetes in the continuum of hyperglycemia-when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:2–14.
60.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71. CrossRefPubMed

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.